ReviewAdvances in therapy2019
Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime.
Review in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06660823 (Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery
Who cites it
36 citing papers in PubMed, 85 citations in OpenAlex.
- Extra levothyroxine dose in Ramadan maintained normal thyroid hormone levels in patients with hypothyroidism: a randomized controlled trial.Frontiers in endocrinology · 2025Trial
- Comment on Higher Post-Operative L-Thyroxine Dosage Needed After Right Compared to Left-Lobe Hemithyroidectomy.Endocrinology, diabetes & metabolism · 2026Article
- Post-Levothyroxine Thyroid Dysfunction in Saudi Arabian Patients with Hypothyroidism: A Cross-Sectional Study.Clinics and practice · 2026Article
- Association Between the Levothyroxine Therapy and the Levels of Anti-Thyroid Antibodies in Women with Hypothyroidism Due to Hashimoto's Thyroiditis-Narrative Review.International journal of molecular sciences · 2026Review
- Review
- The effectiveness of levothyroxine starting doses after thyroidectomy is compromised by early body variations occurring after surgery.Endocrine · 2026Article
- Thyroid Hormone Replacement Dose Is Not Associated with Anti-TPO and Anti-TG Antibody Titers in Hashimoto's Disease.Journal of clinical medicine · 2026Article
- Clinical Course and Risk Factors of Lenvatinib-Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study.Cancer reports (Hoboken, N.J.) · 2026Article
- Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation.Cardiovascular diabetology · 2025Observational
- Prevalence of hypothyroidism among patients undergoing thyroid function tests in primary healthcare centres in Dubai, UAE.BMC public health · 2025Article
- Developing a machine learning-based predictive model for levothyroxine dosage estimation in hypothyroid patients: a retrospective study.Frontiers in endocrinology · 2025Article
- Levothyroxine dose prediction post-thyroidectomy for differentiated thyroid carcinoma.Frontiers in endocrinology · 2025Article
- One sip of water with LT-4 supplementation-a key to euthyroidism in Hashimoto's thyroiditis.Endocrine · 2024Article
- Genetically predicted hypothyroidism, thyroid hormone treatment, and the risk of cardiovascular diseases: a mendelian randomization study.BMC cardiovascular disorders · 2024Article
- Color Doppler ultrasound and real-time elastography in patients with hypothyroidism for the prediction of levothyroxine replacement: a cross-sectional study of 338 patients.Journal of ultrasound · 2024Article
- Cryopreserved Thyroid Tissue Autotransplant in Pediatric Age Patients: A Feasibility Study and Literature Review.Cancers · 2024Article
- Association of pharmacogenomic, clinical and behavioural factors with oral levothyroxine (LT-4) dose of hypothyroid patients in Sri Lanka: a matched case control study.BMC medical genomics · 2024Article
- Analysis of dose-TSH response effect of levothyroxine soft-gel formulation.Frontiers in endocrinology · 2024Article
- Deiodinase Type 3 Polymorphism (rs1190716) Affects Therapeutic Response to Levothyroxine.Turkish journal of pharmaceutical sciences · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levothyroxine is the standard therapy for patients with hypothyroidism, a condition that affects up to 5% of people worldwide. While levothyroxine therapy has substantially improved the lives of millions of hypothyroid patients since its introduction in 1949, the complexity of maintaining biochemical and clinical euthyroidism in patients undergoing treatment with levothyroxine cannot be underestimated. Initial dosing of levothyroxine can vary greatly and may be based on the amount of residual thyroid function retained by the patient, the body weight or lean body mass of the patient, and thyroid-stimulating hormone levels. As levothyroxine is usually administered over a patient's lifetime, physiological changes throughout life will affect the dose of levothyroxine required to maintain euthyroidism. Furthermore, dose adjustments may need to be made in patients with concomitant medical conditions, in patients taking certain medications, as well as in elderly patients. Patients who have undergone any weight or hormonal changes may require dose adjustments, and the majority of pregnant women require increased doses of levothyroxine. Optimal treatment of hypothyroidism requires a partnership between patient and physician. The physician is tasked with vigilant appraisal of the patient's status based on a thorough clinical and laboratory assessment and appropriate adjustment of their levothyroxine therapy. The patient in turn is tasked with medication adherence and reporting of symptomatology and any changes in their medical situation. The goal is consistent maintenance of euthyroidism, without the patient experiencing the adverse events and negative health consequences of under- or overtreatment.Funding Merck.Plain Language Summary Plain language summary available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.